NCT05784688 - Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

March 10, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

Solid TumorBiliary Tract CancerHead and Neck Squamous Cell CarcinomaColorectal Cancer

Interventions

DRUG

TU2218 + KEYTRUDA® (Pembrolizumab)

TU2218: Orally administered KEYTRUDA® (Pembrolizumab): Intravenously administered

Trial Locations (11)

75701

ACTIVE_NOT_RECRUITING

Hope Cancer Center, Tyler

99208

ACTIVE_NOT_RECRUITING

Medical Oncology, Spokane

78229-3307

ACTIVE_NOT_RECRUITING

NEXT Oncology, San Antonio

Unknown

RECRUITING

CHA University Bundang Medical Center, Seongnam

RECRUITING

Seoul National University Bundang Hospital, Seongnam

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

RECRUITING

Severance Hospital, Seoul

RECRUITING

The Catholic University of Korea Seoul St. Mary Hospital, Seoul

RECRUITING

The Catholic University of Korea St. Vincent's Hospital, Suwon

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

TiumBio Co., Ltd.

INDUSTRY